Menu ×


Benign Prostatic Hyperplasia Treatment Market Segmentation by Treatment Type [Drug {Alpha Blockers (Alfuzosin, Doxazosin, Tamsulosin, and Terazosin), 5-Alpha Reductase Inhibitors (Finasteride and Dutasteride), and Phosphodiesterase 5 inhibitors} and Surgery (TURP, TUMT, TUNA, Laser, Urolift Therapy, Prostatic Stenting, Rezum Therapy and Others)]; and by Application (General Medical & Surgical Hospitals, Clinics, and Others) – Global Demand Analysis and Opportunity Outlook 2021-2029

  • Text Size:

Inflation And Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022.

Request Insights

Purchasing power in the couPurchasing power in the country is expected to fell nearly by 2.5%. On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.                                                         Request Insights

Read More

Benign Prostatic Hyperplasia Treatment Market Highlights 2020-2029

The benign prostatic hyperplasia treatment market is estimated to grow with a moderate CAGR during the forecast period, i.e., 2021-2029. Rising prevalence of benign prostatic hyperplasia due to growth of geriatric population on a global level, along with increasing preference for minimally invasive surgeries are expected to fuel the progress of this market. The growth of the market can also be attributed to factors such as increasing obesity rate and advancement of research in the field of benign prostate hyperplasia treatment. According to the data collected from National Center for Biotechnology Information, clinical benign prostate hyperplasia is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms. The prevalence of benign prostate hyperplasia increases after the age of 40 years, with a prevalence of 8%-60% at age 90 years.


The market is segmented based on treatment type [drug {alpha blockers (alfuzosin, doxazosin, tamsulosin, and terazosin), 5-alpha reductase inhibitors (finasteride and dutasteride), and phosphodiesterase 5 inhibitors} and surgery (TURP, TUMT, TUNA, laser, urolift therapy, prostatic stenting, rezum therapy and others)], out of which, the drug treatment segment is anticipated to grab the largest share by the end of 2021 on account of its use as a first line of treatment among men with moderate symptoms. However, surgery segment is also projected to contribute to the growth of this market during the forecast period due to increasing adoption of minimally invasive surgeries by patients with severe symptoms. CLICK TO DOWNLOAD SAMPLE REPORT

On the basis of application, the general medical and surgical hospitals segment in the benign prostatic hyperplasia treatment market is projected to grow with a significant CAGR over the forecast period. The growth of the segment can be attributed to the fact that they are early adopters of technologically advanced treatments for benign prostatic hyperplasia which gives them an advantage over other segments.

Benign Prostatic Hyperplasia Treatment Market Regional Synopsis

Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the rising elderly population in the region which is most likely to be an important factor for rise in cases of benign prostatic hyperplasia. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing investment of governmental and non-governmental agencies in research, accompanied by the increasing geriatric and obese population. Alternatively, the market in Europe is also anticipated to occupy a significant share in the benign prostatic hyperplasia treatment market on account of high adoptability of minimal invasive surgical procedures for treating benign prostatic hyperplasia. According to National Centre for Biotechnology Information, over 4 million patients acquire healthcare-associated infections in the European Union every year.


The benign prostatic hyperplasia treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the benign prostatic hyperplasia treatment market includes the following segments:

By Treatment Type

  • Drug
  • Surgery

By Application

  • General Medical & Surgical Hospitals
  • Specialty Hospitals
  • Clinics
  • Others

Growth Drivers

  • Rising prevalence of benign prostatic hyperplasia due to growth of geriatric population on a global level
  • Increasing preference for minimally invasive surgeries


  • Limited applicability of drug treatment in terms of patients
  • High costs of surgery which becomes difficult to be financed by the elderly population

Top Featured Companies Dominating the Market

  • Boston Scientific Corporation
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Olympus Corporation
  • Abbott
  • Coloplast Group
  • GlaxoSmithKline PLC
  • Merck & Co.
  • Eli Lilly
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions | LOB

Copyright © 2022 Research Nester. All Rights Reserved